2026 CMT Biobank Dates and Cities Are Here

by | Feb 15, 2026 | 1 comment

🩸2026 CMT Biobank Dates + Cities Are Here!

The CMT Biobank continues to drive critical research forward — and we’re excited to announce our 2026 collection dates and cities.

Are we coming to a city near you?

HNF is seeking individuals with a CMT diagnosis to participate in the CMT Biobank. By donating a small blood sample and allowing your de-identified GRIN data to be shared, you’ll help researchers:

Develop cell models for all CMT subtypes

Advance therapeutic targets

Identify important CMT biomarkers

Participation is simple — and there is no cost to participate.

Our partner, COMBINEDBrain, will be collecting samples at the following locations. You may visit ANY of these cities.

Interested in Participating in CMT Research?

Who

Anyone diagnosed (via EMG or genetic test) with Charcot-Marie-Tooth.

We also need a small number of non-affected sibling controls.

What

COMBINEDBrain and HNF will collect a small blood sample to be stored in the CMT Biobank, supporting biomarker projects and other GRIN Advisory Council-approved research.

2026 CMT Biobank Collection Cities & Dates

Ann Arbor, MI — June 27–28

Asheville, NC — July 14–15

Austin, TX — November 7

Bethesda, MD — July 20

Boston, MA — June 27–28

Boston, MA — Date TBD

Cambridge, MA — July 18

Concord, NC — June 24–25

Denver, CO — June 13–14

Denver, CO — December 3–4

Ellicott City, MD — April 16–17 (HNF Summit)

Galveston, TX — July 20–21

Orlando, FL — April 9–10

Philadelphia, PA — July 17–18

Philadelphia, PA — October 9–10

San Antonio, TX — March 19–20

How to Participate

Simply complete the interest form and select the location closest to you.

Your participation helps accelerate research for all CMT subtypes — and brings us closer to meaningful treatments.

Fill out the form below today and join us in advancing CMT research.

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Join the conversation

Leave a Comment

1 Comment

  1. Karen E. Kostiuk

    2 gene mutations confirmed as pathogenic/Heterozygous. EMG confirmed + nerve evaluation through skin punch biopsy. Fig4 c.122t>c and MCM3AP c.112_113del I so want to donate blood, saliva and tissue samples for research.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news